Genenta Science SPA
NASDAQ:GNTA
Genenta Science SPA
NASDAQ:GNTA
Price:
0.6301
USD
-1.55%
Market Closed
Market Cap:
$26.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Genenta Science SPA
NASDAQ:GNTA
|
IT |
|
Partners Group Holding AG
OTC:PGPHF
|
CH |
|
Cellcom Israel Ltd
F:F5U
|
IL |
|
Athabasca Oil Corp
F:ATI
|
CA |
|
L
|
Lectra SA
SWB:LET
|
FR |
|
Butn Ltd
ASX:BTN
|
AU |
|
S
|
Sunrise Communications Ltd
SIX:SUNN
|
CH |
|
Midland Exploration Inc
OTC:MIDLF
|
CA |
|
I
|
Itron Inc
DUS:IT6
|
US |
|
Doubleview Gold Corp
F:1D4
|
CA |
|
C29 Metals Ltd
F:OF0
|
AU |
|
K
|
Kroger Co
XMUN:KOG
|
US |
|
L
|
Liaoning Port Co Ltd
SWB:D7P
|
CN |
|
F
|
FGI Industries Ltd
NASDAQ:FGI
|
US |
|
A
|
Aevis Victoria SA
SIX:AEVS
|
CH |
|
C
|
Corbion NV
F:CSU
|
NL |
Intrinsic Value
Not Available for GNTA
There is not enough data to reliably calculate the intrinsic value for Genenta Science SPA.
Do our valuations actually work? See backtest results .
Alternatives to GNTA
Fundamental Analysis
What Genenta Science SPA Does
Genenta Science is a biotechnology company that develops gene therapy treatments for cancer. Its main idea is to take a patient’s blood-forming stem cells, modify them in the lab, and use them to deliver anti-tumor signals inside the body. The company’s lead work is centered on Temferon, a platform designed to help the immune system attack solid tumors from within the tumor environment.
- Headquarters
- Italy IT
- Employees
- 9
- IPO date
- Dec 15, 2021
Financials
Efficiency
Earnings Waterfall
Genenta Science SPA
Genenta Science SPA
